NewAmsterdam Pharma Company N.V. $NAMS Shares Purchased by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 1.4% in the 4th quarter, HoldingsChannel reports. The firm owned 16,943,774 shares of the company’s stock after purchasing an additional 241,818 shares during the period. NewAmsterdam Pharma makes up 16.0% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its biggest position. Frazier Life Sciences Management L.P. owned 0.15% of NewAmsterdam Pharma worth $594,388,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its stake in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN grew its stake in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. Navalign LLC acquired a new position in NewAmsterdam Pharma during the 4th quarter worth $46,000. Empowered Funds LLC acquired a new position in NewAmsterdam Pharma during the 4th quarter worth $85,000. Finally, NBC Securities Inc. acquired a new position in NewAmsterdam Pharma during the 4th quarter worth $86,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. The trade was a 72.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $30.40 on Friday. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -16.98 and a beta of 0.07. The business has a 50-day moving average of $33.44 and a two-hundred day moving average of $33.69. NewAmsterdam Pharma Company N.V. has a 1 year low of $17.63 and a 1 year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million during the quarter. As a group, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Truist Financial assumed coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 target price for the company. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC boosted their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.